The Keap1-Nrf2-antioxidant response element pathway: a review of its regulation by melatonin and the proteasome
GLP-1 Safety Disclaimer: GLP-1 receptor agonist medications carry documented safety information including risk of pancreatitis, gallbladder disease, acute kidney injury, hypoglycemia (particularly in combination with insulin or sulfonylureas), serious hypersensitivity reactions, and - for FDA-approved tirzepatide and semaglutide products - a Boxed Warning regarding risk of thyroid C-cell tumors
Adherence and lifestyle factors are crucial determinants of success
GLP-1 receptor agonists have become increasingly popular, and its easy to see why
Browse all Pip pen needle options For more general sizing context (including pen needles for traditional insulin pens), see Pip's existing Lancet & Pen Needle Size Guide and the Pen Needles & Insulin Syringes: Ultimate Guide
Further studies to determine the accuracy of GUS in the setting of GLP-1 RAs would be beneficial to set guidelines for the preoperative use of GUS in the setting of GLP-1 RA, as well as clarifying uncertainty within these guidelines among these patients